Medtronic (MDT) Competitors

Medtronic has higher revenue and earnings than GE HealthCare Technologies. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

In the previous week, Medtronic had 10 more articles in the media than GE HealthCare Technologies. MarketBeat recorded 24 mentions for Medtronic and 14 mentions for GE HealthCare Technologies. Medtronic's average media sentiment score of 0.90 beat GE HealthCare Technologies' score of 0.67 indicating that Medtronic is being referred to more favorably in the media.

Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 2.8%. GE HealthCare Technologies pays an annual dividend of $0.16 per share and has a dividend yield of 0.2%. Medtronic pays out 70.9% of its earnings in the form of a dividend. GE HealthCare Technologies pays out 3.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Medtronic has raised its dividend for 49 consecutive years and GE HealthCare Technologies has raised its dividend for 1 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

82.1% of Medtronic shares are owned by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are owned by institutional investors. 0.3% of Medtronic shares are owned by company insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Medtronic has a net margin of 13.93% compared to GE HealthCare Technologies' net margin of 9.96%. GE HealthCare Technologies' return on equity of 20.45% beat Medtronic's return on equity.

Medtronic presently has a consensus price target of $102.88, suggesting a potential upside of 0.04%. GE HealthCare Technologies has a consensus price target of $82.17, suggesting a potential downside of 1.02%. Given Medtronic's stronger consensus rating and higher probable upside, research analysts plainly believe Medtronic is more favorable than GE HealthCare Technologies.

Medtronic has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

82.1% of Medtronic shares are held by institutional investors. Comparatively, 83.6% of Intuitive Surgical shares are held by institutional investors. 0.3% of Medtronic shares are held by company insiders. Comparatively, 0.6% of Intuitive Surgical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Intuitive Surgical had 14 more articles in the media than Medtronic. MarketBeat recorded 38 mentions for Intuitive Surgical and 24 mentions for Medtronic. Intuitive Surgical's average media sentiment score of 1.12 beat Medtronic's score of 0.90 indicating that Intuitive Surgical is being referred to more favorably in the news media.

Intuitive Surgical has a net margin of 25.54% compared to Medtronic's net margin of 13.93%. Intuitive Surgical's return on equity of 18.17% beat Medtronic's return on equity.

Medtronic has higher revenue and earnings than Intuitive Surgical. Medtronic is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Medtronic presently has a consensus price target of $102.88, indicating a potential upside of 0.04%. Intuitive Surgical has a consensus price target of $493.54, indicating a potential upside of 11.26%. Given Intuitive Surgical's stronger consensus rating and higher probable upside, analysts plainly believe Intuitive Surgical is more favorable than Medtronic.

Medtronic has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Intuitive Surgical has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

Abbott Laboratories has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Medtronic has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

In the previous week, Abbott Laboratories had 8 more articles in the media than Medtronic. MarketBeat recorded 32 mentions for Abbott Laboratories and 24 mentions for Medtronic. Abbott Laboratories' average media sentiment score of 1.16 beat Medtronic's score of 0.90 indicating that Abbott Laboratories is being referred to more favorably in the media.

75.2% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 0.5% of Abbott Laboratories shares are owned by company insiders. Comparatively, 0.3% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Abbott Laboratories pays an annual dividend of $2.52 per share and has a dividend yield of 2.3%. Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 2.8%. Abbott Laboratories pays out 94.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Medtronic pays out 70.9% of its earnings in the form of a dividend. Abbott Laboratories has raised its dividend for 54 consecutive years and Medtronic has raised its dividend for 49 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and lower payout ratio.

Abbott Laboratories currently has a consensus target price of $118.32, indicating a potential upside of 8.96%. Medtronic has a consensus target price of $102.88, indicating a potential upside of 0.04%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, equities analysts clearly believe Abbott Laboratories is more favorable than Medtronic.

Medtronic has a net margin of 13.93% compared to Abbott Laboratories' net margin of 9.75%. Abbott Laboratories' return on equity of 18.04% beat Medtronic's return on equity.

Abbott Laboratories has higher revenue and earnings than Medtronic. Medtronic is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Medtronic has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Boston Scientific has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

Boston Scientific has a net margin of 16.62% compared to Medtronic's net margin of 13.93%. Boston Scientific's return on equity of 18.61% beat Medtronic's return on equity.

Medtronic presently has a consensus price target of $102.88, suggesting a potential upside of 0.04%. Boston Scientific has a consensus price target of $61.43, suggesting a potential upside of 38.59%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Boston Scientific is more favorable than Medtronic.

Medtronic has higher revenue and earnings than Boston Scientific. Boston Scientific is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

82.1% of Medtronic shares are held by institutional investors. Comparatively, 89.1% of Boston Scientific shares are held by institutional investors. 0.3% of Medtronic shares are held by insiders. Comparatively, 0.3% of Boston Scientific shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Medtronic had 3 more articles in the media than Boston Scientific. MarketBeat recorded 24 mentions for Medtronic and 21 mentions for Boston Scientific. Boston Scientific's average media sentiment score of 1.10 beat Medtronic's score of 0.90 indicating that Boston Scientific is being referred to more favorably in the news media.